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Introduction: The association between estrogen receptor (ER) gene 
polymorphism and lung cancer risk is rarely studied. This study 
aimed to explore the ER gene polymorphisms associated with the 
lung adenocarcinoma risk in never-smoking women.
Methods: This study evaluated 532 never-smoking female patients 
with lung adenocarcinoma and 532 healthy controls. The ESR1 and 
ESR2 single nucleotide polymorphism (SNP) data were retrieved 
from a genome-wide association study. Using a multivariate-adjusted 
logistic regression assay, the associations of ESR1 and ESR2 SNPs 
with the lung adenocarcinoma risk were estimated. Expression 
quantitative trait loci analysis was performed to investigate the pos-
sible functional roles of ER gene SNPs.
Results: For ESR1, seven tagged SNPs were identified. Among them, 
rs7753153 and rs985192 were associated with lung adenocarcinoma 
risk (rs7753153: odds ratios [OR], 1.509; 95% confidence intervals 
[CI], 1.168–1.950; rs985192: OR, 1.309; 95% CI, 1.001–1.712). For 
ESR2, only rs3020450 was associated with lung adenocarcinoma 
risk (OR, 2.110; 95% CI, 1.007–4.422). Subjects without hormone 
replacement therapy (HRT) use carrying at-risk genotypes had a sig-
nificantly higher lung adenocarcinoma risk than subjects with HRT 
carrying no at-risk genotypes (rs7753153 GG: OR, 2.133; 95% CI, 
1.415–3.216; rs985192 AA/AC, OR: 1.752, 95% CI: 1.109–2.768; 
rs3020450 AG/GG, OR: 7.162, 95% CI: 1.608–31.90). Risk geno-
types of rs7753153 (p = 0.0248) and rs9479122 (p = 0.0251) were 
associated with decreased ESR1 expression.
Conclusions: ER gene SNPs are associated with lung adenocarci-
noma risk in never-smoking women. The joint effects of ER gene 
SNPs and HRT use on lung adenocarcinoma risk highlight the impor-
tance of the gene–environment interaction in lung carcinogenesis.
Key Words: Estrogen receptor, Polymorphism, Lung cancer, 
Hormone replacement therapy, Carcinogenesis.
(J Thorac Oncol. 2015;10: 1413–1420)
Lung cancer remains the leading cause of cancer death world-wide.1 Previous global statistics estimate that one-fourth 
of lung cancer patients are never smokers, including 53% of 
women and 15% of men.2 Another report in Singapore dem-
onstrated that 32.4% of non–small-cell lung cancer patients 
are never smokers, with 14.6% among men and 72.8% among 
women.3 In that study, the major histologic type is adenocarci-
noma (69.9%), especially among women (75.0%). In Taiwan, 
more than 90% of women lung cancer patients were never 
smokers, with a high percentage of adenocarcinoma (75%).4 
Lung cancer in never smokers is a unique disease entity sepa-
rate from smoking-related lung cancer. Determining the risk 
factors associated with lung carcinogenesis in this never-
smoking population has become increasingly important.
Several studies support that estrogen could promote 
lung cancer proliferation, either in vitro or in vivo.5–7 Estrogens 
mainly interact with two subtypes of estrogen receptors (ER), 
ERα8 and ERβ,9 to exert molecular action. In breast cancer, 
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ERα expression is increased, and ERβ overexpression inhib-
its estrodiol-stimulated cancer cell proliferation.10 Such ERs 
were found in varying degrees in human non–small-cell lung 
cancer.11–15 This indicated that ERα and ERβ may play a role 
in lung carcinogenesis.
ER gene polymorphisms have been reported to be asso-
ciated with risks of breast cancer,16,17 endometrial cancer,18 and 
prostate cancer.19 However, the association between ER gene 
polymorphism and lung cancer risk is seldom reported. A case–
control study in the United States showed no association between 
ESR2 haplotypes and lung cancer risk.20 Another recent study in 
Taiwan found that ERα gene PvuII and XbaI polymorphisms are 
associated with non–small-cell lung cancer risk.21
To test the hypothesis that there may be an association 
between ER gene polymorphisms and lung carcinogenesis 
in never-smoking women, this case–control study was con-
ducted, with ESR1 and ESR2 single nucleotide polymorphism 
(SNP) data retrieved from a genome-wide association study 
(GWAS) on lung adenocarcinoma in never-smoking woman.22
The gene–environment interaction may play a role 
in lung carcinogenesis. Our previous study demonstrated 
the impact of the interaction between hormone replacement 
therapy (HRT) and epidermal growth factor receptor (EGFR) 
polymorphism on lung adenocarcinoma risk,23 based on the 
crosstalk between EGFR and ER pathways. Because estrogen 
may interact with ER more directly than with EGFR, we fur-
ther examined potential joint effects of ER gene SNPs and 
HRT on the risk of lung adenocarcinoma.
METHODS
Study Population
This case–control study is a part of an ongoing coop-
erative study in Taiwan, the Genetic Epidemiological Study 
of Lung Adenocarcinoma (GELAC). From September 2002 
to December 2009, patients were recruited from six medical 
centers. Never-smoking female patients with lung adenocarci-
noma confirmed by pathologic or cytologic examination were 
enrolled. All subjects were Taiwanese and older than 18 years. 
Lung cancer histology was classified according to the World 
Health Organization criteria.24 Patients with a previous history 
of cancer were excluded.
During the case recruitment period, control subjects 
were also recruited from the six medical centers. They were 
cancer-free individuals randomly selected from the health 
examination clinics of the same hospitals. Controls with a his-
tory of cancer were excluded. The control subjects were all 
never smokers and matched 1:1 to the case subjects based on 
age and sex. This study is approved by the institutional review 
board of each hospital.
Genotyping Analysis
The methods of genotyping were described in the previ-
ous GWAS.24 Briefly, genomic DNA was extracted from blood 
samples, and the Illumina HumanHap610 Quad BeadChip on 
contract at deCODE Genetics in Iceland was used. A total of 
550 cases and 549 controls were genotyped in the GWAS. 
Quality control metrics were performed to exclude SNPs if 
(1) there was a minor allele frequency less than 5%; (2) the 
call rate was less than 90%; and (3) SNPs had a missing rate 
between 0.02 and 0.1 and nonrandom genotype failure with 
p less than 0.02, and significant deviation from fitness from 
the Hardy–Weinberg equilibrium (p < 0.0001 in controls). 
To deal with the population substructure issue so as to avoid 
spurious association in conducting the GWAS,22 we applied 
pairwise population concordance test in PLINK25 to cluster 
individuals into homogeneous subsets and to identify outly-
ing individuals (http://pngu.mgh.harvard.edu/purcell/plink/). 
Based on pairwise population concordance test, we found 
two clusters; a large cluster consisting of self-reported Han 
Chinese and a small cluster of 12 people consisting of mainly 
self-reported aborigines. The 12 subjects in the small cluster 
were excluded from further analysis. The remaining 532 cases 
and 532 controls with 457,504 SNPs passed quality control. 
The ESR1 and ESR2 SNPs passing the quality control were 
retrieved from the GWAS data. To define linkage disequilib-
rium patterns, SNP genotyping data from the 532 controls 
were uploaded to HaploView 4.2.26
Data Collection
The personal interview was conducted by a trained 
research nurse. All of the study participants provided written 
informed consent for blood sample collection and personal 
interview. Information on age; education level; body mass index 
(BMI, kg/m2); active and passive cigarette smoking; cumula-
tive duration of HRT and contraceptive medication; number of 
pregnancies, deliveries, and miscarriages; menopausal status; 
history of cooking fume exposure; history of oophorectomy; 
and family history of malignancies were collected.
The use of HRT was defined as a history of either 
estrogen replacement therapy or estrogen and progestin 
combination therapy for a cumulative duration of at least 3 
months. Contraceptive use was defined as a history of con-
traceptive medication for a cumulative duration of at least 3 
months. Subjects were defined as “ever cigarette smokers” if 
she smoked cigarettes regularly for more than 6 months.27,28 
Otherwise, they were defined as never smokers. Passive ciga-
rette smoking was defined as inhalation of other people’s ciga-
rette smoke at the workplace or by living with family members 
who smoked.
The body weight of healthy controls was recorded upon 
enrollment. For the cases, their body weight was recorded 
according to the value while in a healthy state, so as to avoid 
underestimating the BMI because of cancer-related body 
weight loss. Cooking fume exposure was defined by continu-
ous cooking for no less than 6 months. The sum of cooking 
fume exposure (cooking time-years) was calculated by mul-
tiplying cooking intensity (times per day) by the duration of 
cooking (years). A family history of breast, ovary, cervix, 
or endometrial cancer in first-degree female relatives was 
recorded.
Statistical Analysis
Differences between the case and control groups were 
analyzed by Pearson’s χ2 test in variables including education; 
passive smoking status; HRT use; contraceptive medication; 
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menopausal status; number of pregnancies, deliveries, and 
miscarriages; family history of common malignancies in 
women; and cooking fume exposure.
Univariate logistic regression analyses were performed 
to assess the effects of variables on the risk of lung adenocar-
cinoma. Variables with significant differences between the two 
groups were selected for adjustment in multivariate analysis. 
Odds ratios (OR) and 95% confidence intervals (CI) were cal-
culated for logistic regression analyses.
To identify the potential SNPs associated with lung ade-
nocarcinoma risk, a strategy based on the study by Pande et al29 
was designed with modification (Fig. 1). First, a logistic regres-
sion analyses were done to test the association between each SNP 
and lung adenocarcinoma, with adjustments for statistically sig-
nificant covariates found by univariate analyses. Second, to filter 
highly correlated SNPs, those SNPs with p less than 0.05 were 
screened by tagging using Tagger, a program of Haploview,26 
developed by Broad Institute of MIT and Harvard (Cambridge, 
MA). Haplotype blocks were then constructed from the tagged 
SNPs. Lastly, stepwise forward selection logistic regression was 
performed for model selection and for selecting the tagged SNPs 
that had an association, while adjusting for significant covari-
ates. The joint effects of putative high-risk SNPs genotypes in 
the final model and HRT use on lung adenocarcinoma risk, with 
adjustments for covariates, were also assessed.
The SAS system for Windows version 8.2 (SAS Institute 
Inc., NC) was used for all statistical analyses. All of the tests 
were two-sided. Statistical significance was set at p less than 
0.05. For internal model validation, the bootstrap was used.30 
A bootstrap SAS Macro developed by Johnson31 was used for 
calculating bootstrap estimates of OR in logistic regression. For 
each bootstrap estimate of OR, 10,000 bootstrap replications 
were conducted.
Expression Quantitative Trait Loci Assay
A lung cancer tissue cohort (LCTC) was complied from 
lung cancer patients underwent surgical operation in China 
Medical University Hospital, Taiwan, as part of the GELAC 
study supported by the National Research Program of Genomic 
Medicine, Taiwan. This was approved by the Institutional Review 
Board of the National Health Research Institutes and that of China 
Medical University. We obtained the informed consent of each 
subject in the LCTC and collected his/her tumor tissue and adja-
cent normal tissue, in addition to blood and clinical information.
For some of the LCTC subjects, microarray experiments 
were conducted to obtain their expression levels in both the 
tumor tissue and the adjacent normal tissue, using Illumina 
WG-DASL HumanRef8 v3 or HumanHT12 v4 BeadChip. 
Genome-scale genotype data based on DNA from buffy coat 
were also obtained for some of these subjects, using Illumina 
Human 660W Quad BeadChip (Illumina Inc., San Diego, CA).
Preprocessing of the microarray expression data 
included standard quality control (per Illumina’s instruc-
tions), model-based background correction,32 and surro-
gate variable analysis to detect and alleviate batch effects.33 
This resulted in expression level at 24,216 probes; here, the 
intersection of the two Illumina probe sets was considered. 
Using PLINK,25 we performed systematic quality control on 
the genotype data to remove poor SNPs and poor samples 
in the same manner as in our GWAS22; these resulted in 
441,297 SNPs for analysis.
Finally, we obtained the genome-scale expression and 
genotype data of 115 nonsmoking patients with lung adeno-
carcinoma, referred to as the subcohort LCTCNS. The expres-
sion data used in this study can be found in the dataset Gene 
Expression Omnibus with accession number GSE46539. To 
further explore the other genes expression that may potentially 
associated with the risk genotype of ESR1 and ESR2, expression 
quantitative trait loci (eQTL) analyses were performed cover-
ing the genes in 1000 kb upstream and downstream of ESR1 and 
ESR2. Because rs9479122 is not genotyped in the patients of the 
LCTCNS, we obtained imputed genotype data for them, using 
IMPUTE234 and CHB[ASN] and CHS[ASN] in 1000 Genomes 
Project (Jun 2011 release) as reference panel; CHB[ASN] and 
CHS[ASN] have, respectively, 97 and 100 samples.
RESULTS
Clinical Characteristics
The demographic data of cases and control subjects 
were reported in a previous study concerning the interaction 
between EGFR polymorphisms and HRT use.23 The mean 
age was 60.55 years for the case group, and 60.41 years for 
the control group (p = 0.833). There were significant differ-
ences the two groups in terms of the proportion of HRT use 
(case versus control, 25.53% versus 31.57%, p = 0.032), pas-
sive smoking (case versus control, 76.79% versus 70.44%, 
p = 0.021), educational level (years, >12, 7–12, <7; case 
versus control, 12.97% versus 17.34%; 27.44% versus 
31.60%, 59.59% versus 51.06%, p = 0.016), and cooking 
fume exposure period (time-year, >110, 60–110, 10–60, 
≤10; case versus control, 29.21% versus 22.68%, 26.50% 
FIGURE 1.  The algorithm to investigate the retrieved ESR1 
single nucleotide polymorphisms.
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versus 35.70%, 33.27% versus 28.21%, 11.03% versus 
13.41%, p = 0.002). These variables were selected for 
adjustment in the multivariate analysis. No significant dif-
ferences were found between the patients and controls in 
the other variables including BMI, menopause, contracep-
tives use, miscarriage, pregnancy, delivery, oophorectomy, 
family history of breast, cervical, ovarian, or endometrial 
cancers, and cooking fumes exposure.
Analysis of ESR1 and ESR2 SNPs 
Retrieved from GWAS Data
For ESR1, a total of 98 SNPs were retrieved and ana-
lyzed. Among them, rs532010, rs9479122, rs7753153, 
rs11155813, rs827423, rs9322336, rs3020317, rs985192, 
rs3003925, and rs985694 were associated with lung adeno-
carcinoma risk, without adjustment for multiple compari-
son effects (Supplementary Table 1, Supplementary Digital 
Content 1, http://links.lww.com/JTO/A864). Using the 
Tagger program, seven tagged SNPs were screened (Table 1), 
including rs532010 (p = 0.0190), rs9479122 (p = 0.0252), 
rs7753153 (p = 0.0008), rs9322336 (p = 0.0139), rs985192 
(p = 0.0233), rs3003925 (p = 0.0418), and rs985694 
(p = 0.0260). All bootstrap estimates of ORs were very close 
to estimates from the multivariate models (Table 1).
One haplotype block, block 1, was constructed to 
identify SNP sets in linkage disequilibrium among the seven 
tagged SNPs (Fig. 2). A stepwise forward selection logis-
tic regression approach was used for the seven SNPs, with 
adjustment for HRT, education level, passive smoking, and 
cooking fume exposure. The SNPs rs7753153 and rs985192 
were significantly associated with lung adenocarcinoma 
exposure (rs7753153: OR, 1.509; 95% CI, 1.168–1.950; 
rs985192: OR, 1.309; 95% CI, 1.001–1.712; Table 2). All 
bootstrap estimates of the ORs were very close to estimates 
from the multivariate models (Table 2).
For ESR2, 20 SNPs were retrieved and analyzed. Only 
rs3020450 was associated with lung adenocarcinoma risk, 
without adjustment for multiple comparison effects (OR, 
2.110; 95% CI, 1.007–4.422; p = 0.0478; Supplementary 
Table 2, Supplementary Digital Content 2, http://links.lww.
com/JTO/A865).
TABLE 1.  The Association of Seven Tagged ESR1 SNPs with Lung Adenocarcinoma Risk, with Bootstrap Analysis
SNP Genotype Case Control
OR  
(95% CI)
Adjusted 
P Valuea
Bootstrap 
ORa
rs532010 GA + GG 297 (55.83%) 331 (62.22%) 1 0.0190 1
AA 235 (44.17%) 201 (37.78%) 1.361 (1.052–1.761) 1.363
rs9479122 AA + AG 112 (21.09%) 147 (27.68%) 1 0.0252 1
GG 419 (78.91%) 384 (72.32%) 1.398 (1.042–1.875) 1.402
rs7753153 AA + AG 224 (42.11%) 271 (50.94%) 1 0.0008 1
GG 308 (57.89%) 261 (49.06%) 1.544 (1.197–1.992) 1.551
rs9322336 AA 181 (34.02%) 221 (41.54%) 1 0.0139 1
GA + GG 351 (65.98%) 311 (58.46%) 1.387 (1.069–1.799) 1.391
rs985192 CC 167 (31.39%) 195 (36.65%) 1 0.0233 1
AA + AC 365 (68.61%) 337 (63.35%) 1.360 (1.043–1.775) 1.366
rs3003925 AA + GA 459 (86.28%) 479 (90.04%) 1 0.0418 1
GG 73 (13.72%) 53 (9.96%) 1.511 (1.015–2.249) 1.517
rs985694 GG 140 (26.32%) 168 (31.58%) 1 0.0260 1
AA + AG 392 (73.68%) 364 (68.42%) 1.371 (1.039–1.810) 1.379
aAdjusted for education level, cooking time-year, hormone replacement therapy, and passive smoking.
SNPs, single nucleotide polymorphisms; CI, confidence interval; OR, odds ratio.
FIGURE 2.  The linkage disequilibrium pattern of seven 
tagged ESR1 single nucleotide polymorphisms (SNPs) interact-
ing with hormone replacement therapy (HRT) use, denoted by 
r2 values and shading. The correlation between the SNPs was 
indicated by the level of r2 values and the density of shading.
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Joint Effects of ER Gene SNP and HRT 
Use on Lung Adenocarcinoma Risk
The joint effects of ER SNPs and HRT use on the risk of 
lung adenocarcinoma are revealed in Table 3. For ESR1, subjects 
not using HRT and carrying the at-risk genotypes of rs7753153 
and rs985192 had significantly higher risks of developing lung 
adenocarcinoma than those with HRT use and without the at-
risk genotypes (no HRT + rs7753153 GG, OR, 2.133; 95% CI, 
1.415–3.216; no HRT + rs985192 AA/AC, OR, 1.752; 95% 
CI, 1.109–2.768). In contrast, for ESR2, subjects without HRT 
use and carrying the at-risk genotypes of rs3020450 had sig-
nificantly higher risks of developing lung adenocarcinoma than 
those with HRT use and not carrying the at-risk genotypes (no 
HRT + rs7753153 AG/GG, OR, 7.162; 95% CI, 1.608–31.90).
All bootstrap estimates of the ORs in ESR1 were very 
close to estimates from the multivariate models. The bootstrap 
estimates of OR in ESR2 SNP were higher than the original 
OR, which might be due to the small sample size.
Position and Functional Location 
of ESR1 and ESR2 SNPs Associated 
with Lung Adenocarcinoma Risk 
in Never-Smoking Women
The positions and functional locations of the seven 
tagged ESR1 SNPs associated with lung adenocarcinoma risk 
are listed in Table 4. The ESR1 SNP rs532010, rs9479122, and 
rs7753153, which were categorized in a haplotype block, are 
all located in intron 3. The SNP rs9322336 is located in intron 
4, whereas rs985192, rs3003925, and rs985694 are in intron 6. 
The ESR2 SNP rs3020450 is located in 5′ UTR, the promoter 
region.
Expression Quantitative Trait Loci Assay
We performed eQTL analysis for the seven tagged 
ESR1 SNPs and the ESR2 SNP, rs3020450. Among the ESR1 
SNPs, rs7753153 risk genotype GG and rs9479122 risk geno-
type GG were associated with decreased expression of ESR1 
(rs7753153, β= −0.0919, p = 0.0248; rs9479122, β= −0.1014, 
p = 0.0251). For ESR2, no association was found between the 
rs3020450 risk genotype and ESR2 expression.
SNP rs7753153 risk genotype GG was associ-
ated with decreased expression of AKAP12 (β = −0.2113, 
p = 0.0110) and increased expression of PLEKHG1 (β=0.0641, 
p = 0.0139). SNP rs985192 risk genotype AA + AC were asso-
ciated with the decreased expression of AKAP12 (β = −0.0874, 
p = 0.0308) and increased expression of RMND1 (β = 0.0985, 
p = 0.0091). A borderline association was found between SNPs 
rs985694 risk genotype AA + GA and decreased expression of 
VIP (β=−0.1520, p = 0.0477).
The ESR2 SNP rs3020450 risk genotype AG + 
GG was associated with increased expression of SYNE2 
(β = 0.1533, p = 0.0279) and decreased expression of MTHFD1 
TABLE 2.  The ESR1 SNPs Associated with Lung 
Adenocarcinoma Risk Selected by a Stepwise Forward 
Selection Logistic Regression Approach, with Bootstrap 
Analysis
SNP Genotype
OR  
(95% CI)
Adjusted 
P Valuea
Bootstrap 
ORa
rs7753153 AA + AG 1 0.0017 1
GG 1.509 (1.168–1.950) 1.513
rs985192 CC 1 0.0489 1
AA + AC 1.309 (1.001–1.712) 1.314
aAdjusted for education level, cooking time-year, hormone replacement therapy, and 
passive smoking.
SNPs, single nucleotide polymorphisms; CI, confidence interval; OR, odds ratio.
TABLE 3.  The Joint Effects of ESR1 and ESR2 SNP and Hormone Replacement Therapy on Lung Adenocarcinoma Risk, with 
Bootstrap Analysis
Gene/SNP Genotype/HRT Case Control Odds Ratio
Adjusted 
P Valuea
Bootstrap  
Odds Ratio
ESR1
  rs7753153 AA/AG + HRT use 54 (10.36%) 85 (16.25%) 1 1
AA/AG + no HRT use 166 (31.86%) 183 (34.99%) 1.439 (0.949–2.180) 0.0863 1.442
GG + HRT use 79 (15.16%) 78 (14.91%) 1.709 (1.061–2.752) 0.0275 1.731
GG + no HRT use 222 (42.61%) 177 (33.84%) 2.133 (1.415–3.216) 0.0003 2.154
  rs985192 CC + HRT use 41 (7.87%) 56 (10.71%) 1 1
CC + No HRT use 123 (23.61%) 136 (26.00%) 1.255 (0.770–2.045) 0.3631 1.254
AA/AC + HRT use 92 (17.66%) 107 (20.46%) 1.269 (0.764–2.109) 0.3573 1.274
AA/AC + No HRT use 265 (50.86%) 224 (42.83%) 1.752 (1.109–2.768) 0.0162 1.754
ESR2
  rs3020450 AA + HRT use 2 (0.38%) 14 (2.68%) 1 1
AA + no HRT use 10 (1.92%) 9 (1.72%) 5.945 (1.028–34.38) 0.0465 26.27
AG/GG + HRT use 131 (25.14%) 149 (28.49%) 5.789 (1.285–26.08) 0.0222 26.03
AG/GG + no HRT use 378 (72.55%) 351 (67.11%) 7.162 (1.608–31.90) 0.0098 32.09
Subjects carrying GG genotype of rs7753153, AA/AC genotype of rs985192, and AG/GG genotype of rs3020450 were considered as at risk.
aAdjusted for education level, cooking time-year, and passive smoking.
SNP, single nucleotide polymorphism; HRT, hormone replacement therapy. 
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(β = −0.0783, p = 0.0274), ZBTB25 (β = −0.1169, p = 0.0314), 
and SPTB (β = −0.7382, p = 0.0002).
DISCUSSION
This study demonstrates the association between ER 
gene SNPs and the risk of lung adenocarcinoma in never-
smoking women. In subjects without HRT use, there is a sig-
nificant increase in lung adenocarcinoma risk while carrying 
the at-risk genotypes of ER gene SNPs.
None of the seven tagged ESR1 SNPs has been reported 
to be associated with lung cancer risk. Three SNPs are clus-
tered in a haplotype block located in intron 3, which may 
indicate the possible association with lung cancer risk in 
this region. SNP rs532010 is associated with lipolytic sensi-
tivity to noradrenaline.35 SNP rs9322336 is associated with 
increased risk of musculoskeletal toxicity-related exemestane 
discontinuation in breast cancer patients,36 whereas rs985694 
is associated with the risk of type two diabetes mellitus.37 No 
associations were reported between these seven SNPs and 
breast cancer risk.
In the 20 ESR2 SNPs retrieved, only rs3020450 is sig-
nificantly associated with lung adenocarcinoma risk. This 
SNP is located in the promoter region of ESR2, which is in the 
5′ region directly adjacent to the transcription start site. There 
are several studies on the association of rs3020450 and lipid 
disorders or malignancies other than lung cancer. It is associ-
ated with an increased risk of developing lipoatrophy in HIV-
infected patients on Highly Active Antiretroviral Therapy.38 
However, rs3020450 has been tested in case–control studies, 
which showed no association with risks of endometrial car-
cinoma, breast cancer, and fibroid tumor.39–42 Further stud-
ies on the influence of rs3020450 on the ESR2 function are 
warranted.
In eQTL analysis for ESR1 SNPs, the risk genotypes of 
rs7753153 and rs9479122 were associated with the decreased 
expression of ESR1. So far, no previous studies reported the 
association between rs7753153, rs9478122, and ERα expres-
sion. These risk genotypes may be associated with low ERα 
expression and attenuate the protective effect of HRT in 
never-smoking women. AKAP12 is a gene encoding A-kinase 
anchoring protein 12, which is methylated in lung cancer.43 
The risk genotypes of rs7753153 and rs985192, two SNPs in 
the multivariate analysis model associated with lung adeno-
carcinoma risk, were associated with the decreased expres-
sion level of AKAP12. This finding may suggest the potential 
interaction between AKAP12 expression and ESR1 SNPs in 
lung carcinogenesis. PLEKHG1 encodes pleckstrin homol-
ogy domain-containing family G member 1. RMND1 encodes 
the protein, required for meiotic nuclear division 1 homolog, 
which is located in the C6ORF97-ESR1 locus associated 
with breast cancer susceptibility.44 Whether PLEKHG1 and 
RMND1 were associated with ESR1 expression is not clear.
In contrast, ESR2 SNP rs3020450 were associated with 
increased expression of SYNE2 and decreased expression 
of MTHFD1, ZBTB25, and SPTB. SYNE2 encodes spec-
trin repeat containing nuclear envelope 2, which is a nuclear 
outer membrane protein binding F-actin in cytoplasm. Beta-
spectrin, encoded by SPTB, is a cytoskeletal protein existed 
mainly in erythrocyte.45 ZBTB25 is considered as a transcrip-
tion factor.46 The genetic variant of MTHFD1 was reported 
to be associated with prognosis of lung cancer patients.47 The 
association between these gene expression and lung adeno-
carcinoma risk has not yet been studied. Further functional 
studies are warranted.
Recently, Schwartz et al48 reported that HRT and estro-
gen use is only associated with a reduced risk of histopatho-
logically ERα-positive and/or ERβ-positive non–small-cell 
lung cancer. Among postmenopausal women, none of the 
hormone-related variables are associated with nuclear ERα-
negative and/or ERβ-negative non–small-cell lung cancer.48 
In breast cancer, a joint effect of ER sequence variants and 
endogenous estrogen exposure on breast cancer risk has been 
also reported.49 This study demonstrates the joint effects of ER 
gene SNPs and HRT use on the risk of lung adenocarcinoma. 
When studying the association between HRT and lung cancer 
risk, the interaction between ER SNPs and HRT use should be 
considered.
In the past few years, there have been several GWASs 
conducted for lung cancer.50–56 Almost all have been con-
ducted to detect the main effect of genetic variants. Thus, few 
data concerning gene–environment interactions are presented 
in the GWASs. In our study, the cases had more exposure 
to fumes and passive smoking and less use of HRT. Among 
subjects with different environmental exposures, susceptibil-
ity alleles for lung cancer may be masked by heterogeneity. 
These masked genetic variants can be identified by analyz-
ing GWAS data with environmental exposure information. 
Environmental exposure, which may modify cancer risk in 
individuals harboring certain gene polymorphisms, can be 
also clarified. Previously, HRT use been demonstrated to have 
a protective effect on lung carcinogenesis in women.57 In this 
study, ESR1 and ESR2 SNPs have been further retrieved from 
GWAS data to disclose their joint effects with HRT use on lung 
adenocarcinoma risk. These findings may help in identifying 
high-risk subjects in lung cancer screening. Further studies 
on gene polymorphisms interact with cooking fume exposure 
period and passive smoking may be helpful for understanding 
the mechanism of lung carcinogenesis.
TABLE 4.  Position and Functional Location of ESR1 and ESR2 
SNPs Associated with Lung Adenocarcinoma Risk in Never-
Smoking Women
Gene Name Position
Functional 
Location
ESR1 rs532010a 152172611 Intron 3
rs9479122a 152182633 Intron 3
rs7753153a 152189791 Intron 3
rs9322336 152242123 Intron 4
rs985192 152325171 Intron 6
rs3003925 152326151 Intron 6
rs985694 152328318 Intron 6
ESR2 rs3020450 63838055 5′ UTR
aClustered in haplotype block 1.
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There are major limitations in this study. First, this 
study is a secondary analysis from a molecular epidemio-
logic study on susceptibility markers of lung cancer. The 
case number is relatively small in comparison with other 
population-based studies. However, despite its limited case 
number, this study is the first on the joint effects of ER gene 
SNPs and HRT on lung cancer risk in never-smoking women. 
These findings suggest that the association between ER gene 
SNP and lung adenocarcinoma risk may be modified by HRT 
use and indicate that adjustments of environmental factors, 
like HRT use, are important in genetic epidemiologic studies 
on lung carcinoma risk in women. Second, this study is lack 
of an independent validation from other studies. However, 
studies recruited never-smoking subjects in lung carcinogen-
esis are few. These findings should be validated by further 
large population-based studies on never-smoking subjects. 
Third, the bootstrap analysis was used for internal validation 
because it is often used with increasing popularity in model 
validation. However, the bootstrap theory involves showing 
consistency of the estimate, for which large sample size may 
be required. If the sample size is small, the bootstrap analy-
sis may not work well because the set of possible bootstrap 
samples is not rich enough. It should be noted that to inves-
tigate the joint effects of SNP and HRT, the bootstrap esti-
mates of OR for internal validation in ESR2 SNP rs3020450 
were larger than the original OR. In this case, the bootstrap 
estimates cannot work well because the sample size for sub-
jects carrying AA genotype with HRT use is small.
At last, this is a hospital-based case–control study, there 
might be a healthy-volunteer effect for the controls recruited 
from the health examination department. Although one study 
on hormonal factors and the risk of non–small-cell lung can-
cer demonstrated similar results for hospital-based and popu-
lation-based controls,58 our results should be interpreted with 
caution. Selecting the cases only from those who previously 
attended the health examination departments will make cases 
and controls more comparable.
In conclusion, ER gene SNPs may be associated with 
lung adenocarcinoma risk in never-smoking women. The joint 
effects of ER gene SNP and HRT use highlight the importance 
of the gene–environment interaction in lung carcinogenesis 
among never-smoking women.
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